Shares of Silo Pharma, Inc. (SILO) are surging more than 50% Friday morning after the company reported positive data for its drug candidate SPU-21 for the treatment of Arthritis.
The company today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents.
Silo Pharma said it is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).
SILO, currently at $5.21, has traded in the range of $0.17-$12.45 in the last 1 year.
Source: Read Full Article
Lates News:
-
Bitcoin ($BTC) Price Could Be in “Early Stages” of a Short Squeeze, Says Popular on-Chain Analyst Willy Woo
-
K33 Research Highlights Unwavering Institutional Demand for Bitcoin
-
Still Bullish: Billionaire Money Manager Bill Miller Maintains View Bitcoin Will Rise Again Despite FTX Chaos
-
Vipshop Holdings Still Up On Improved Q2 Results
-
Surge In Core Inflation Drags Cryptos Lower